Clinical Trial Update: Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating vaginal DHEA for vaginal atrophy and menopausal symptoms in postmenopausal breast cancer survivors on aromatase inhibitors was terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Postmenopausal Symptoms
• Vaginal Atrophy

Drugs mentioned

• Intrarosa (prasterone) vaginal insert (prasterone)

Snippet

Sponsor: University of Arkansas | Conditions: Vaginal Atrophy, Postmenopausal Symptoms | Phase 2 | Status: TERMINATED | Results posted: 2024-09-23